Williams S F, Zimmerman T, Grad G, Mick R
Department of Medicine, University of Chicago Medical Center, IL 60637.
J Hematother. 1993 Winter;2(4):521-3. doi: 10.1089/scd.1.1993.2.521.
Sustained hematopoiesis can be restored after dose-intensive chemotherapy utilizing stem cells from either bone marrow and/or peripheral blood. Numerous reports have demonstrated the effectiveness of peripheral blood progenitors (PBPC) in restoring hematopoiesis. Here, we review data comparing the recovery among patients rescued with various stem cell sources after dose-intensive therapy. PBPC used alone or to augment autologous bone marrow to achieve timely hematopoietic recovery after dose-intensive therapy can result in shortened hospital stays, decreased transfusion requirements, and antibiotic usage. This will lead to increased application of dose-intensive therapy either singly or in multiple courses to treat various malignancies.
利用来自骨髓和/或外周血的干细胞进行剂量密集化疗后，可持续造血功能可得以恢复。众多报告已证实外周血祖细胞（PBPC）在恢复造血功能方面的有效性。在此，我们回顾了比较剂量密集治疗后采用各种干细胞来源进行挽救的患者之间恢复情况的数据。单独使用PBPC或用其增强自体骨髓，以在剂量密集治疗后实现及时的造血恢复，可缩短住院时间、减少输血需求及抗生素使用。这将导致剂量密集治疗单独或多疗程应用增加，以治疗各种恶性肿瘤。
